FeesSafety
Pluang+

Instil Bio reports Q3 2026 loss of $4.2M, cash to fund operations through 2027

Company Fundamentals
16 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Neutral
Instil Bio reports Q3 2026 loss of $4.2M, cash to fund operations through 2027

Instil Bio announced its financial results for Q3 2026, reporting a net loss of $4.2 million, significantly lower than the $13.6 million loss in the same period last year. The company holds $67.1 million in cash and investments, expected to support operations through 2027. Instil is focused on building a portfolio of asset-focused subsidiaries to develop novel therapies, with reduced research and development expenses compared to 2025. The company also corrected minor prior financial statement errors, maintaining transparency with investors.

Instil Bio reported a net loss of $4.2 million in Q3 2026, a significant improvement from the previous year's $13.6 million loss. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 16, 2026 18:12 WIB: out of 150 priced US health stocks, 66 rose and 50 fell. Notable movers include Dyne Therapeutics Inc. (DYN) at USD 17.50 with a 1-day change of +1.98%, Recursion Pharmaceuticals Inc. (RXRX) at USD 3.13 with -1.73%, and Takeda Pharmaceutical Company Limited (TAK) at USD 21.80 with +1.73%.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
1 hour ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
1 hour ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
1 hour ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
2 hours ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App